Oppenheimer Holdings Inc. reissued their hold rating on shares of Opko Health Inc. (NYSE:OPK) in a research note published on Monday morning.
A number of other analysts have also recently weighed in on OPK. Zacks Investment Research cut Opko Health from a hold rating to a sell rating in a research report on Friday, July 1st. Jefferies Group reaffirmed a hold rating on shares of Opko Health in a research report on Wednesday, August 17th. Standpoint Research increased their price objective on Opko Health from $16.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, June 21st. Deutsche Bank AG decreased their price objective on Opko Health from $11.00 to $10.00 and set a hold rating for the company in a research report on Thursday, June 16th. Finally, JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the stock a buy rating in a research report on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $13.20.
Shares of Opko Health (NYSE:OPK) opened at 9.56 on Monday. The stock has a market capitalization of $5.26 billion and a PE ratio of 40.00. Opko Health has a 52-week low of $7.12 and a 52-week high of $11.85. The stock has a 50 day moving average price of $10.07 and a 200-day moving average price of $10.08.
Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. The firm’s revenue for the quarter was up 742.2% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. On average, equities research analysts anticipate that Opko Health will post ($0.05) EPS for the current fiscal year.
In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was purchased at an average cost of $9.88 per share, with a total value of $98,800.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $30,321,235.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC purchased a new position in Opko Health during the second quarter valued at $100,000. Financial Architects Inc increased its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in Opko Health during the second quarter valued at $103,000. Williams Jones & Associates LLC increased its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock valued at $106,000 after buying an additional 8,800 shares during the last quarter. Finally, Nuveen Fund Advisors LLC purchased a new position in Opko Health during the second quarter valued at $131,000.
Opko Health Company Profile